ArticleFrontiers in surgery2025
Clinical application of enhanced recovery after surgery in bipolar transurethral vaporization of prostate for benign prostatic hyperplasia.
Article in Frontiers in surgery, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: To explore the clinical application of enhanced recovery after surgery (ERAS) in bipolar transurethral vaporization of the prostate (B-TUVP) and its impact on postoperative recovery. Methods: A retrospective analysis was conducted on the clinical data of 212 patients with benign prostatic hyperplasia (BPH) admitted to the Department of Urology of our hospital from January 2019 to December 2024. Among them, 121 patients were managed under an ERAS protocol (ERAS group), and 91 patients received traditional perioperative care (control group). The clinical characteristics included age, mean body mass index (BMI), preoperative comorbidities, prostate volume (PV), preoperative International Prostate Symptom Score (IPSS), preoperative Quality of Life (QoL) score, preoperative urinary flow rate, and urodynamic parameters. Preoperative management, intraoperative management, and postoperative outcomes were compared between the two groups. Results: The clinical baseline data showed no significant differences between the two groups. Compared with the control group, the ERAS group had a significantly shorter duration of continuous bladder irrigation, time to first ambulation, and postoperative length of stay ( Conclusion: The application of the ERAS protocol in B-TUVP can promote postoperative recovery, reduce the postoperative length of stay, and decrease total hospitalization costs. However, more prospective randomized controlled trials are needed to further validate the feasibility and effectiveness of this protocol.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.